HOOK vs. TLSA, ONCY, ACRS, BRNS, VACC, ANIX, CMRX, SLS, SPRO, and ALRN
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Tiziana Life Sciences (TLSA), Oncolytics Biotech (ONCY), Aclaris Therapeutics (ACRS), Barinthus Biotherapeutics (BRNS), Vaccitech (VACC), Anixa Biosciences (ANIX), Chimerix (CMRX), SELLAS Life Sciences Group (SLS), Spero Therapeutics (SPRO), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical preparations" industry.
Tiziana Life Sciences (NASDAQ:TLSA) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
Tiziana Life Sciences received 10 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 69.35% of users gave Hookipa Pharma an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote.
Tiziana Life Sciences has a net margin of 0.00% compared to Tiziana Life Sciences' net margin of -88.73%. Hookipa Pharma's return on equity of 0.00% beat Tiziana Life Sciences' return on equity.
63.9% of Hookipa Pharma shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 3.3% of Hookipa Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Hookipa Pharma had 6 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Hookipa Pharma and 2 mentions for Tiziana Life Sciences. Hookipa Pharma's average media sentiment score of 1.88 beat Tiziana Life Sciences' score of 0.72 indicating that Tiziana Life Sciences is being referred to more favorably in the media.
Tiziana Life Sciences has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Tiziana Life Sciences has higher earnings, but lower revenue than Hookipa Pharma.
Hookipa Pharma has a consensus target price of $4.67, suggesting a potential upside of 483.26%. Given Tiziana Life Sciences' higher possible upside, analysts clearly believe Hookipa Pharma is more favorable than Tiziana Life Sciences.
Summary
Tiziana Life Sciences and Hookipa Pharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
